Bitget’s July Report Highlights Bitget Wallet Becomes the Largest Integrated Wallet in the TON EcosystemVICTORIA, Seychelles, Aug. 09, 2024 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has released its monthly report highlighting the ecosystem’s updates for July 2024. Bitget Wallet’s MPC wallet solution supports the TON mainnet, which allows users to easily create and import wallets via email. This positioned Bitget Wallet as the largest integrated wallet in the TON ecosystem. Not just this, Bitget Wallet surpassed popular apps like TikTok and WhatsApp in Nigeria with 200% in the month of June, positioning the wallet as the top choice for Nigeria-based crypto users.
Bitget recorded a notable start to Q3, Forbes recognized BGB in the list of best performing tokens in 2024, and CCData highlighted Bitget’s market share growth among centralized exchanges in the first half of the year. July witnessed the release of various reports and updates from Bitget, enhancing user awareness about the evolving crypto landscape. Bitget listed 33 new tokens, bringing the total count to 873. The total trading volume (TVL) reached $204.3 billion, with a 7.2% monthly growth. Bitcoin (BTC), Ethereum (ETH), XRP and Solana (SOL) led the top 10 cryptocurrencies by TVL, followed by PEPE, WLD, WIF, NOT, ZRO, and MEW – all memecoins.
In a strategic partnership with Upland, Bitget launched the utility token SPARKLET on Ethereum. This collaboration included establishing Bitget’s virtual headquarters in Upland’s metaverse, featuring extensive token airdrops and rewards for both communities. Bitget acquired Treasure Island, consisting of 888 properties. Additionally, Upland’s token, SPARKLET, was exclusively listed on Bitget’s launchpool, giving users a competitive advantage.
On the research side, Bitget in collaboration with Nansen, released insights on token-discovery strategies. The report provides traders with essential information and strategies for investing in early-stage projects. By evaluating data sets correlated to token prices, Bitget and Nansen offer valuable insights for traders.
The platform retained 25 million users with a daily trading volume of $10 billion. It currently hosts over 180,000 professional traders and 800,000+ copy trading followers. With over 80 million successful trades, users gained $500 million, and elite traders shared $23 million in profits. The platform offers 800+ tokens and 900+ spot trading pairs, with a daily spot trading volume of $400 million and $7 billion in USDT-M Futures.
For more information, please visit the monthly report here.
About Bitget
Established in 2018, Bitget is the world’s leading cryptocurrency exchange and Web3 company. Serving over 25 million users in 100+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, swap, NFT Marketplace, DApp browser, and more. Bitget inspires individuals to embrace crypto through collaborations with credible partners, including legendary Argentinian footballer Lionel Messi and Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team).
Operational complementarities expected to yield annual synergies of approximately $100 million
Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform
Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods
Highly complementary pipeline with approximately 10 clinical readouts expected over the next 18 months
Industry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion overall before potential royalties over the course of the partnership
Well-capitalized balance sheet with approximately $850 million in cash and cash equivalents between the two companies as of the end of Q2 2024
Operational complementarities expected to yield annual synergies in excess of $100 million
SALT LAKE CITY and OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) today announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster.
“We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion as well as the planned CEO of the combined entity. “Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started.”
“Adding Exscientia’s best-in-class focused precision oncology internal pipeline to Recursion’s first-in-class focused pipeline spanning rare disease, precision oncology and infectious disease is highly complementary as we look to bring treatments to patients faster,” said David Hallett, Ph.D., Interim Chief Executive Officer and planned Chief Scientific Officer of Recursion post-closing of the transaction. “We look forward to bringing our teams together and integrating Recursion’s high throughput and target biology capabilities with Exscientia’s highly scalable molecular design and automated chemistry synthesis capabilities to truly accelerate the discovery of better drugs for patients.”
Once integrated, the companies believe the extended and evolved Recursion OS will enable the discovery and translation of higher quality medicines more efficiently and at a higher scale with a full-stack technology-enabled small molecule discovery platform. In addition, the combined company expects to read out approximately 10 clinical trials in the next 18 months.
The proposed business combination will also advance significant therapeutic discovery collaborations with some of the most prominent biopharma companies in the world, including Roche-Genentech, Sanofi, Bayer, and Merck KGaA. Moreover, there is the potential for approximately $200 million in milestone payments over the next 2 years from these current partnerships and there is the potential for more than $20 billion in revenue before royalties on net-sales of partnership programs which range from mid single-digit to double-digit royalties over the course of the partnership.
Recursion & Exscientia Combined Pipeline
Recursion & Exscientia Combined Pipeline
Strategic Rationale
Pipeline: The combination would create a diverse portfolio of clinical and near-clinical programs (approximately 10 clinical readouts expected in the next 18 months) where most of these programs, if successful, could have annual peak sales opportunities in excess of $1 billion. In addition to Recursion’s internal pipeline, Exscientia has wholly-owned oncology programs associated with targets CDK7 (clinical), LSD1, and MALT1 as well as partnered programs associated with targets PKC-Theta (clinical) and ENPP1. Across the combined pipeline there is no competitive overlap, with Recursion’s pipeline focusing on first-in-class drug candidates within oncology, rare disease, and infectious disease and Exscientia’s focus on best-in-class drug candidates within oncology. Additionally, for both companies there are many research and discovery stage pipeline programs that would benefit from the complementary combination of the two platforms.
Partnerships: The proposed business combination would bring together transformational partnerships with leading large pharma companies with a total of 10 programs already optioned across oncology and immunology. In addition to Recursion’s transformational partnerships with Roche-Genentech (neuroscience and a gastrointestinal oncology indication) and Bayer (undruggable oncology), Exscientia has partnerships with Sanofi (immunology and oncology) and Merck KGaA (oncology and immunology). In addition, Exscientia has a partnership with BMS (oncology and immunology) where an optioned program related to PKC-Theta has already shown positive early Phase 1 results. Furthermore, the combined company expects potential additional milestone payments of approximately $200 million over the next 2 years from its current partnerships.
Platform: The combination will help enable a full-stack technology-enabled platform spanning patient-centric target discovery, structure based drug design including hotspot analysis, quantum mechanics and molecular dynamics modeling, 2D and 3D generative AI design, encode and automate design-make-test-learn cycles with active learning, automated chemical synthesis, predictive ADMET and translation, biomarker selection, clinical development, and more. Furthermore, Exscientia’s automated chemistry design and synthesis capabilities are expected to allow Recursion to more rapidly and effectively run SAR cycles during hit to lead and lead optimization. These capabilities are expected to generate diverse chemistry to experimentally improve our predictive maps of biology and chemistry.
Transaction Details
Under the terms of the transaction agreement, which were unanimously approved by the boards of directors of both companies, Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share they own, with fractional shares paid in cash. Based on the fixed exchange ratio, Recursion shareholders will own approximately 74% and Exscientia shareholders will own approximately 26% of the combined company, in each case assuming no additional issuance by either company before closing. Major shareholders of each company, including holders of more than 40% of Exscientia shares, have entered into agreements on customary terms and conditions under which they have agreed to vote all their shares in favor of the transaction. There is approximately $850 million in cash and cash equivalents held by both companies at the end of Q2 2024. The combined company is estimated to achieve annual synergies of approximately $100 million with a runway extending into 2027.
The combination is expected to be implemented through a court sanctioned scheme of arrangement under English law and is subject to the satisfaction of customary closing conditions, including the approval of Exscientia shareholders, the approval of Recursion’s stockholders, and the sanction of the High Court of Justice of England and Wales, and the receipt of required regulatory approvals. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close by early 2025.
Listing, Governance and Management
The combined company, which will be named Recursion, will continue to be headquartered in Salt Lake City, Utah, and trade on the NASDAQ, while maintaining a significant presence in the U.K. Chris Gibson, Ph.D., Co-Founder & CEO of Recursion, will serve as CEO of the combined company and David Hallett, Ph.D., Interim Chief Executive Officer & Chief Scientific Officer of Exscientia, plans to join the combined company as Chief Scientific Officer. Two existing Exscientia directors will join the Board of Recursion following the closing of the transaction.
Advisors
Allen & Company LLC acted as exclusive financial advisor to Recursion and Wilson Sonsini Goodrich & Rosati acted as legal counsel. Centerview Partners LLC acted as exclusive financial advisor to Exscientia and A&O Shearman acted as legal counsel.
About Recursion
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale—up to millions of wet lab experiments weekly—and massive computational scale—owning and operating one of the most powerful supercomputers in the world—Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area and London.
About Exscientia
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.
Forward Looking Statements
Statements contained herein which are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the proposed business combination of Recursion and Exscientia and the outlook for Recursion’s or Exscientia’s future business and financial performance such as delivering better treatments to patients, faster and at a lower cost; the discovery and translation of higher quality medicines more efficiently and at a higher scale; helping to enable a full-stack technology-enabled platform; allowing Recursion to more rapidly and effectively run SAR cycles during hit to lead optimization; generating the diverse chemistry to experimentally improve predictive maps; the number and timing of clinical program readouts over the next 18 months; the combined company’s first-in-class and best-in-class opportunities; potential for sales from successful programs with annual peak sales opportunities of over $1 billion each; potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion in revenue before royalties over the course of the partnerships; percentage of the combined company to be received by Exscientia shareholders; cash runway extending into 2027; the value of estimated annual synergies; implementing the combination through a UK scheme of arrangement; the expected closing of the transaction by early 2025; continuing to build the best example of the next generation of biotechnology companies; the plans for David Hallett, Ph.D. to join the combined company as Chief Scientific Officer; and many others. Such forward-looking statements are based on the current beliefs of Recursion’s and Exscientia’s respective management as well as assumptions made by and information currently available to them, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may vary materially from these forward-looking statements based on a variety of risks and uncertainties including: the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the inability to obtain Recursion’s stockholder approval or Exscientia’s shareholder approval or the failure to satisfy other conditions to completion of the proposed combination, including obtaining the sanction of the High Court of Justice of England and Wales to the Scheme of Arrangement, on a timely basis or at all, and the receipt of required regulatory approvals; risks that the proposed combination disrupts each company’s current plans and operations; the diversion of the attention of the respective management teams of Recursion and Exscientia from their respective ongoing business operations; the ability of either Recursion, Exscientia or the combined company to retain key personnel; the ability to realize the benefits of the proposed combination, including cost synergies; the ability to successfully integrate Exscientia’s business with Recursion’s business, at all or in a timely manner; the outcome of any legal proceedings that may be instituted against Recursion, Exscientia or others following announcement of the proposed combination; the amount of the costs, fees, expenses and charges related to the proposed combination; the effect of economic, market or business conditions, including competition, regulatory approvals and commercializing drug candidates, or changes in such conditions, have on Recursion’s, Exscientia’s and the combined company’s operations, revenue, cash flow, operating expenses, employee hiring and retention, relationships with business partners, the development or launch of technology enabled drug discovery, and commercializing drug candidates; the risks of conducting Recursion’s and Exscientia’s business internationally; the impact of changes in interest rates by the Federal Reserve and other central banks; the impact of potential inflation, volatility in foreign currency exchange rates and supply chain disruptions; the ability to maintain technology-enabled drug discovery in the biopharma industry; and risks relating to the market value of Recursion’s common stock to be issued in the proposed combination.
Other important factors and information are contained in Recursion’s most recent Annual Report on Form 10-K and Exscientia’s most recent Annual Report on Form 20-F, including the risks summarized in the section entitled “Risk Factors,” Recursion’s most recent Quarterly Reports on Form 10-Q and Exscientia’s filing on Form 6-K filed May 21, 2024, and each company’s other periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed at https://ir.recursion.com in the case of Recursion, http://investors.exscientia.ai in the case of Exscientia, or www.sec.gov. All forward-looking statements are qualified by these cautionary statements and apply only as of the date they are made. Neither Recursion nor Exscientia undertakes any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional Information and Where to Find It
This communication relates to a proposed business combination of Recursion and Exscientia that will become the subject of a joint proxy statement to be filed by Recursion with the SEC. The joint proxy statement will provide full details of the proposed combination and the attendant benefits and risks, including the terms and conditions of the scheme of arrangement and the other information required to be provided to Exscientia’s shareholders under the applicable provisions of the U.K. Companies Act 2006. This communication is not a substitute for the joint proxy statement or any other document that Recursion or Exscientia may file with the SEC or send to their respective stockholders in connection with the proposed combination. Investors and security holders are urged to read the definitive joint proxy statement and all other relevant documents filed with the SEC or sent to Recursion’s stockholders or Exscientia’s shareholders as they become available because they will contain important information about the proposed combination. All documents, when filed, will be available free of charge at the SEC’s website (www.sec.gov). You may also obtain these documents by contacting Recursion’s Investor Relations department at investor@recursion.com; or by contacting Exscientia’s Investor Relations department at investors@exscientia.ai. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.
Participants in the Solicitation
Recursion, Exscientia and their respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed business combination. Information about Recursion’s directors and executive officers is available in Recursion’s proxy statement dated April 23, 2024 for its 2024 Annual Meeting of Stockholders. Information about Exscientia’s directors and executive officers is available in Exscientia’s proxy statement dated March 21, 2024 for its 2024 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement and all other relevant materials to be filed with the SEC regarding the proposed combination when they become available. Investors should read the joint proxy statement carefully when it becomes available before making any voting or investment decisions.
Inaugural Winners to Be Celebrated at a Ceremony in New York on September 16
Winners in First Annual Stevie® Awards for Technology Excellence Announced
The awards celebrate the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors.
FAIRFAX, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) — Winners in the 2024 (first annual) Stevie® Awards for Technology Excellence, “the Olympics for technology,” were announced today. The awards celebrate the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors. Individuals and organizations worldwide are eligible to enter – public and private, for-profit and non-profit, large and small.
Among the organizations with multiple Stevie Award wins are Amazon/Amazon Web Services (9), IBM (5), the City of Sydney, Australia (4), Gabriel Marketing Group, on behalf of several of their clients (4), Impel (4), LandGate (4), Lenovo/Lenovo India Pvt Ltd/ Lenovo PCCW Solutions (LPS) (4), BostonGene (3), Cisco Systems Inc. (3), CleverTap (3), Google (3), Gov2Biz Inc (3), MicroHealth, LLC (3), and Three Rings (3).
Winners will be celebrated during a gala awards banquet on Monday, September 16 at the Marriott Marquis Hotel in New York City. Tickets are now on sale. The presentations will be broadcast live.
More than 600 nominations from organizations in 21 nations and territories were evaluated in this year’s competition. Winners were determined by the average scores of more than 100 professionals worldwide, acting as judges. The Stevie Awards for Great Employers recognize achievement in many facets of the workplace. Categories are grouped in 20 technology-industry sections:
Advertising, Marketing & Public Relations Technology
Aerospace Technology
Agricultural Technology
Architectural Technology
Artificial Intelligence
Assistive Technology
Biotechnology
Business Technology
Communication Technology
Educational Technology
Energy Technology
Entertainment Technology
Financial Technology
Government Technology
Green and Clean Technology
Healthcare Technology
Information Technology
Manufacturing Technology
Marine Technology
Transportation Technology
The awards are presented by the Stevie Awards, organizer of nine of the world’s leading business awards shows including the prestigious International Business Awards® and American Business Awards®.
About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Technology Excellence, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.
Optimize collaboration across Zoom Workplace with next-gen Zoom Docs; transform content from Zoom Meetings into actionable documents with AI Companion
Zoom Docs’ AI-first customizable design easily adapts to team and project needs, including documents, wikis, and tables, providing a single place to manage work
SAN JOSE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) announced the rollout of Zoom Docs, its AI-first collaborative docs solution, starting today. Zoom Docs is powered by Zoom AI Companion, the company’s generative AI assistant available at no additional cost*, to help drive productivity and seamless collaboration throughout Zoom Workplace.
“Zoom Docs is our first Zoom Workplace product with generative AI built in from the ground up; it effortlessly transforms information from Zoom Meetings into actionable documents and knowledge bases, so teams can stay focused on meaningful work,” said Smita Hashim, chief product officer at Zoom. “Zoom Docs is included at no additional cost with Zoom Workplace paid licenses, creating even more value for our customers. With AI Companion available every step of the way, Zoom Docs is purpose-built to empower people to ‘work happy’ and give them more time back in their day.”
Zoom Docs transforms team collaboration
Zoom Docs can help solve critical challenges facing modern workforces, including time wasted on repetitive tasks, information overload, and facilitation of cross-functional alignment. By utilizing Zoom AI Companion to convert meeting outcomes into actionable documents, Zoom Docs can jumpstart content creation and adapt to different individual and team needs to help boost workers’ productivity.
Zoom Docs’ AI-firstcapabilities help Zoom Workplace users make teamwork more collaborative and effective, optimize productivity by keeping information organized, and reduce silos by empowering teams to communicate and share information more fluidly. Potential use cases for Zoom Docs include:
Meeting collaboration: Zoom Docs simplifies meeting collaboration with AI Companion by transforming meeting content into meaningful documents, centralizing meeting summaries with meeting docs, and facilitating co-editing on docs within meetings.
Business documents: Whether creating content, business proposals, or reports, AI Companion for Zoom Docs makes content generation, revision, summarization, and translation easy for global teams.
Project planning: Planning complex projects can be messy. Zoom Docs can help with time-saving templates for project briefs and tracking for a variety of use cases like product launches, marketing campaigns, and event management, consolidating project-related materials, and improving visibility across progress tracking, status updates, and timelines.
Information hub: Useful for knowledge-base creation, team onboarding, and goal tracking, users can build robust wikis for a single source of information.
Additional AI-first capabilities help teams do their best work
With the power of AI Companion, Zoom Docs simplifies work and brings information together for optimal results.
Turn AI Companion meeting summaries into easily editable docs, freeing up time spent on note-taking and manually copying notes into a shared document with templates for one-on-ones, stand-up meetings, brainstorming, project updates, discussions, Q&As, customer success, user feedback, and more.
Generate content based on AI Companion meeting transcripts. Use custom or preset commands or queries with AI Companion to further create and revise content.
Revise and summarize content such as articles, plans, and outlines, change tone and style, catch grammatical and spelling errors, and translate content into nine languages (with support for additional languages planned) for multilingual teams with AI Companion.
Maximize meeting effectiveness to drive better outcomes
Meetings are core to Zoom Workplace, and Zoom Docs builds on that experience by enhancing collaboration before, during, and after meetings, empowering users to stay more aligned and achieve better results.
Start and schedule meetings from a Zoom Doc to connect with colleagues and quickly streamline workflows.
Create, share, and co-edit docs during meetings. Meeting attendees can follow along with the presenter, co-edit, and comment on the doc in real time without leaving the meeting window. Attendees on mobile devices can view in-meeting doc collaboration without signing in.
Create an editable and shareable doc that includes relevant meeting information from a meeting in a customizable format.
Streamline permission sharing to reduce time spent granting access to docs with bulk permission settings for meeting attendees, and the ability to grant temporary access to meeting attendees to collaborate during the meeting. Users can also share Zoom Docs in Team Chat channels and with individuals in specific chats directly from Zoom Docs.
Share docs across Zoom Workplace via Zoom Team Chat or Zoom Mail or invite colleagues to collaborate live in Zoom Meetings to streamline editing.
Get work done in one place for better results
Adapt docs to different individual and team needs to keep collaboration fluid and information organized.
Customize docs with content blocks for texts, tables, images, charts, and more to help increase efficiency and reduce information management across multiple apps. Add data tables for team collaboration and planning to track assignments and projects. Add checklists, images, videos, and callouts to make the doc more engaging, and utilize the multi-column layout for greater flexibility in organizing content.
Embed content from across Zoom Workplace and third parties like Zoom Whiteboard, Google Drive, Figma, X, and YouTube to make information centrally accessible.
Stay organized by starring frequently used docs or quickly filtering docs by author for quick access.
Optimize team collaboration
Reduce silos and keep collaborators informed, connected, and aligned.
Keep an eye on progress using tables, checklists, and trackers for activities, due dates, status, and assigned owners, with various views like Kanban boards, calendars, and galleries.
Organize team documents in dedicated wikis to provide central locations for shared information.
Group, filter, sort, and search datatables to easily visualize information and quickly locate the needed data.
Edit concurrently with up to 100 users in a single Zoom Doc, and tag teammates in edits and comments.
Quickly add, remove, and change permissions for internal teammates and external users to confidently share and collaborate on a doc’s contents.
Zoom Docs with AI Companion is included with all paid Zoom Workplace plans*. Basic (free) users can create up to 10 shared docs and unlimited personal docs without AI Companion but can upgrade to Zoom Workplace Pro, Business, or Enterprise plans for access to AI Companion capabilities across Zoom Workplace, including Docs. Account owners and admins may enable or disable AI Companion for Zoom Docs.
Zoom Docs is available beginning today for users of the Zoom Workplace app, version 6.1.6 or later, which can be downloaded from the Zoom website, and users can also access Zoom Docs from the Docs web homepage or the Zoom Web App.
*Note: AI Companion is included at no additional cost with the paid services assigned to Zoom accounts. AI Companion, including AI Companion capabilities in Zoom Docs, may not be available for all regions and industry verticals.
About Zoom
Zoom’s mission is to provide one platform that delivers limitless human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer care teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.
Zoom Public Relations
Lacretia Nichols
press@zoom.us
The Cloud-Native Solution Enables P&C and General Insurers to Deliver Products at Scale by Eliminating the Need for Upgrades
BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) — Today, Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, announced the general availability of Policy with Active Delivery, a revolutionary solution that eliminates the need for upgrades and enables P&C insurers to deliver insurance products at scale in an era of rapid customer-centric innovation and growth.
Policy with Active Delivery is a cloud-native solution that leverages the power, scalability, and security of the Azure cloud to provide bi-weekly product updates. These updates are applied automatically, assuring there are no disruptions to an insurer’s operations while eliminating the need for additional, costly resources to manage massive upgrades. All updates are “feature flagged,” allowing insurers to choose when to activate them, ensuring zero impact to their production environment.
Policy with Active Delivery also offers low-code configuration tools, an integrated development environment for insurance products, and pre-built content for various lines of business, allowing insurers to go to market faster, increase operational efficiencies, and improve customer satisfaction.
“We are thrilled to introduce Policy with Active Delivery, a game-changing solution that sets a new standard for policy administration in the P&C industry,” said Jess Keeney, Chief Product & Technology Officer of Duck Creek Technologies. “With Active Delivery, insurers can free their IT resources to focus on innovation, rather than maintenance, and respond to the evolving needs of their customers and agents with speed and agility. Policy with Active Delivery is the ultimate expression of our vision to simplify insurance technology and empower our customers to achieve their business goals.”
To drive operational efficiencies, Policy with Active Delivery automates manual processes by leveraging low-code configuration tools for agile updates and enhanced speed to market for new products. These efficiencies translate into reduced expense ratios, improved core operational performance, and enhanced scalability to handle higher volumes seamlessly.
The platform supports omnichannel access, catering to the self-service expectations of customers, agents, and brokers alike. It also enhances underwriting performance by implementing rules-based processing and dynamic workflows, ensuring consistent and optimized outcomes.
About Duck Creek Technologies
Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and X.
Winners to Be Celebrated at a Ceremony in New York on September 16
Winners in the 2024 (ninth annual) Stevie® Awards for Great Employers, “the Olympics for human resources,” have been announced.
More than 1,000 nominations from organizations in 35 nations and territories were evaluated in this year’s competition. Winners were determined by the average scores of more than 130 professionals worldwide, acting as judges.
FAIRFAX, Va., Aug. 05, 2024 (GLOBE NEWSWIRE) — Winners in the 2024 (ninth annual) Stevie® Awards for Great Employers, “the Olympics for human resources,” were announced today. The awards recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work.
Among the organizations with multiple Gold Stevie wins are Bank of America (9), Everise (4), pladis (4), Apexon (3), Digital Hands (3), ecosio (3), Enerjisa Uretim (3), LMI (3), Peak on Air (3), SOCAR Türkiye (3), TurkTraktor (3), Abu Dhabi Customs (2), Arkas Holding (2), Ayala Land, Inc. – Makati Development Corporation (2), Benefex (2), Capital One (2), Cathay United Bank (2), DHL Global Forwarding, Freight (2), Doğuş Holding (2), ENERJISA ENERJI (2), Entek Elektrik (2), Gamefam (2), GCash (Mynt – Globe Fintech Innovations, Inc.) (2), HALKBANK (2), Octopus Energy (2), ResultsCX (2), Seer Medical (2), Tata Consultancy Services (2), Wells Fargo (2), and Wesley, LLC (2).
Winners will be celebrated during a ceremony on Monday, September 16 at the Marriott Marquis Hotel in New York City. Tickets are now on sale. The presentations will be broadcast live.
More than 1,000 nominations from organizations in 35 nations and territories were evaluated in this year’s competition. Winners were determined by the average scores of more than 130 professionals worldwide, acting as judges. The Stevie Awards for Great Employers recognize achievement in many facets of the workplace. Categories include:
Employer of the Year Categories
HR Achievement Categories
HR Individual Categories
HR Team Categories
Solution Provider Categories
Solutions, Implementations, and Training Programs or Media Categories
Thought Leadership Categories
Stevie Award placements in the 31 Employer of the Year categories were be determined by a unique blending of the ratings of professionals and the votes of the general public. More than 34,000 votes were cast this year by members of the public for their favorite employer.
The awards are presented by the Stevie Awards, which organizes nine of the world’s leading business awards shows including the prestigious International Business Awards® and American Business Awards®.
About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Technology Excellence, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.
A sponsor of the 9th annual Stevie Awards for Great Employers is HiBob.
VICTORIA, Seychelles, Aug. 09, 2024 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has released its monthly report highlighting the ecosystem’s updates for July 2024. Bitget Wallet’s MPC wallet solution supports the TON mainnet, which allows users to easily create and import wallets via email. This positioned Bitget Wallet as the largest integrated wallet in the TON ecosystem. Not just this, Bitget Wallet surpassed popular apps like TikTok and WhatsApp in Nigeria with 200% in the month of June, positioning the wallet as the top choice for Nigeria-based crypto users.
GlobeNewswire Distribution ID 9201657
